© 2020 MJH Life Sciences and OncLive. All rights reserved.
November 04, 2018
David M. Jackman, MD, the medical director of Clinical Pathways at Dana-Farber, discusses the benefits of a clinical pathways system.
March 27, 2017
David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).